A PHASE 3, 52-WEEK, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLEBLIND STUDY TO ASSESS THE EFFICACY, SAFETY, AND TOLERABILITY OF ROCATINLIMAB IN
ADULT SUBJECTS WITH PRURIGO NODULARIS WHO ARE INADEQUATELY CONTROLLED ON
TOPICAL THERAPIES OR NOT ELIGIBLE FOR TOPICAL THERAPIES
- Registry ID
- 20230053
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Phase
- PHASE3
- Study type
- INTERVENTIONAL
- Sponsor
- AMGEN CANADA INC
- Start date
- 2024-08-15
- Last update
- 2024-05-29
Conditions
Related clinical trials
- SELECTIVE TREATMENT OF ORAL POVORCITINIB IN PRURIGO NODULARIS STUDY 1 (STOP-PN1). A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EFFICACY AND SAFETY
STUDY OF POVORCITINIB IN PARTICIPANTS WITH PRURIGO NODULARIS.
- SELECTIVE TREATMENT OF ORAL POVORCITINIB IN PRURIGO NODULARIS STUDY 2 (STOPPN2). A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EFFICACY AND SAFETY
STUDY OF POVORCITINIB IN PARTICIPANTS WITH PRURIGO NODULARIS.
- A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF BARZOLVOLIMAB IN PATIENTS WITH PRURIGO NODULARIS
- A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF NEMOLIZUMAB (CD14152) IN SUBJECTS WITH PRURIGO NODULARIS
- A PROSPECTIVE, MULTICENTER, LONG-TERM STUDY TO ASSESS THE SAFETY AND EFFICACY OF NEMOLIZUMAB (CD14152) IN SUBJECTS WITH PRURIGO NODULARIS
View on source registry